JP2015530399A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015530399A5 JP2015530399A5 JP2015532454A JP2015532454A JP2015530399A5 JP 2015530399 A5 JP2015530399 A5 JP 2015530399A5 JP 2015532454 A JP2015532454 A JP 2015532454A JP 2015532454 A JP2015532454 A JP 2015532454A JP 2015530399 A5 JP2015530399 A5 JP 2015530399A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- melphalan
- antibody specific
- pharmaceutical composition
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261705172P | 2012-09-25 | 2012-09-25 | |
| US61/705,172 | 2012-09-25 | ||
| US201361774595P | 2013-03-08 | 2013-03-08 | |
| US61/774,595 | 2013-03-08 | ||
| PCT/EP2013/069858 WO2014048921A1 (en) | 2012-09-25 | 2013-09-24 | Combinations and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015530399A JP2015530399A (ja) | 2015-10-15 |
| JP2015530399A5 true JP2015530399A5 (enExample) | 2016-11-10 |
| JP6426093B2 JP6426093B2 (ja) | 2018-11-28 |
Family
ID=49237209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015532454A Active JP6426093B2 (ja) | 2012-09-25 | 2013-09-24 | 組み合わせ及びその使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9579378B2 (enExample) |
| EP (1) | EP2900232B1 (enExample) |
| JP (1) | JP6426093B2 (enExample) |
| KR (1) | KR102171669B1 (enExample) |
| CN (1) | CN104684552B (enExample) |
| AU (1) | AU2013322806C1 (enExample) |
| BR (1) | BR112015006731A2 (enExample) |
| CA (1) | CA2885792C (enExample) |
| DK (1) | DK2900232T3 (enExample) |
| ES (1) | ES2658953T3 (enExample) |
| HR (1) | HRP20171964T1 (enExample) |
| HU (1) | HUE036518T2 (enExample) |
| IL (1) | IL237926B (enExample) |
| LT (1) | LT2900232T (enExample) |
| MX (1) | MX368288B (enExample) |
| NZ (1) | NZ706147A (enExample) |
| PL (1) | PL2900232T3 (enExample) |
| PT (1) | PT2900232T (enExample) |
| RU (1) | RU2650618C2 (enExample) |
| SG (1) | SG11201502163QA (enExample) |
| WO (1) | WO2014048921A1 (enExample) |
| ZA (1) | ZA201501980B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2860192T3 (pl) * | 2005-10-12 | 2018-03-30 | Morphosys Ag | Wytwarzanie i profilowanie w pełni ludzkich, uzyskanych z HuCAL GOLD terapeutycznych przeciwciał swoistych wobec ludzkiego CD38 |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| PE20170676A1 (es) | 2014-09-09 | 2017-05-22 | Janssen Biotech Inc | Terapias de combinacion con anticuerpos anti-cd38 |
| EA202092609A1 (ru) | 2014-12-04 | 2021-10-29 | Янссен Байотек, Инк. | Антитела к cd38 для лечения острого миелолейкоза |
| CA2986594C (en) | 2015-05-20 | 2025-06-10 | Tufts Medical Center, Inc. | Anti-CD38 antibodies for the treatment of light chain amyloidosis and other CD38-positive hematological malignancies |
| CN107708734B (zh) | 2015-06-22 | 2022-01-11 | 詹森生物科技公司 | 用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤 |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| HUE053366T2 (hu) | 2015-11-03 | 2021-06-28 | Janssen Biotech Inc | Szubkután anti-CD38-ellenanyag-készítmények és alkalmazásuk |
| CN108699161B (zh) * | 2016-03-04 | 2022-06-03 | 莫佛塞斯公司 | 多发性骨髓瘤中m-蛋白应答的临床评估 |
| US20190233533A1 (en) | 2016-06-28 | 2019-08-01 | Umc Utrecht Holding B.V. | Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38 |
| EP3421494A1 (en) * | 2017-06-29 | 2019-01-02 | Sanofi | Use of isatuximab in combination with an anti-pd-1 antibody |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| CN111565751A (zh) | 2017-10-31 | 2020-08-21 | 詹森生物科技公司 | 治疗高危多发性骨髓瘤的方法 |
| IL317328A (en) * | 2018-12-14 | 2025-01-01 | Morphosys Ag | Antibody formulations |
| JP7687956B2 (ja) * | 2019-03-15 | 2025-06-03 | モルフォシス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 自己抗体介在性自己免疫疾患の処置のための、抗ｃｄ３８抗体及びその医薬組成物 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020164788A1 (en) | 1994-12-02 | 2002-11-07 | The Wellcome Foundation Limited | Humanized antibodies to CD38 |
| JP2003524587A (ja) | 1998-06-05 | 2003-08-19 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ | 多発性骨髄腫を処置するための、ｃｄ３８に対する、遺伝子操作した抗体の使用 |
| US7223397B1 (en) | 1999-01-07 | 2007-05-29 | Research Development Foundation | Potentiation of anti-CD38-Immunotoxin cytotoxicity |
| EP1174440A1 (en) | 2000-07-19 | 2002-01-23 | U-BISys B.V. | A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment |
| DE60226641D1 (de) | 2001-12-03 | 2008-06-26 | Amgen Fremont Inc | Antikörperkategorisierung auf der grundlage von bindungseigenschaften |
| ES2541436T3 (es) | 2004-02-06 | 2015-07-20 | Morphosys Ag | Anticuerpos humanos anti-CD38 y usos para ellos |
| EP3312196B1 (en) * | 2005-03-23 | 2019-07-17 | Genmab A/S | Antibodies against cd38 for treatment of multiple myeloma |
| EP1888647A2 (en) | 2005-05-24 | 2008-02-20 | MorphoSys AG | Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38 |
| PL2860192T3 (pl) * | 2005-10-12 | 2018-03-30 | Morphosys Ag | Wytwarzanie i profilowanie w pełni ludzkich, uzyskanych z HuCAL GOLD terapeutycznych przeciwciał swoistych wobec ludzkiego CD38 |
| AU2007302448C1 (en) | 2006-09-26 | 2019-02-14 | Genmab A/S | Combination treatment of CD38-expressing tumors |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| EP2191843A1 (en) * | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide |
| EP2191842A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine |
| EP2191841A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine |
| EP2191840A1 (en) * | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
| EP2580243B1 (en) * | 2010-06-09 | 2019-10-16 | Genmab A/S | Antibodies against human cd38 |
| NZ607473A (en) | 2010-09-27 | 2014-11-28 | Morphosys Ag | Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl |
| UA112170C2 (uk) | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| US20140221319A1 (en) | 2011-06-29 | 2014-08-07 | Mayo Foundation For Medical Education And Research | Small Molecule CD38 Inhibitors and Methods of Using Same |
| JP6279065B2 (ja) | 2013-03-13 | 2018-02-14 | サノフイ | 抗ｃｄ３８抗体およびカーフィルゾミブを含む組成物 |
| CA2909952C (en) | 2013-04-29 | 2021-10-12 | Teva Pharmaceuticals Australia Pty Ltd. | Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b |
-
2013
- 2013-09-24 ES ES13766523.8T patent/ES2658953T3/es active Active
- 2013-09-24 EP EP13766523.8A patent/EP2900232B1/en active Active
- 2013-09-24 HR HRP20171964TT patent/HRP20171964T1/hr unknown
- 2013-09-24 CN CN201380050577.7A patent/CN104684552B/zh active Active
- 2013-09-24 PT PT137665238T patent/PT2900232T/pt unknown
- 2013-09-24 SG SG11201502163QA patent/SG11201502163QA/en unknown
- 2013-09-24 AU AU2013322806A patent/AU2013322806C1/en active Active
- 2013-09-24 KR KR1020157007554A patent/KR102171669B1/ko active Active
- 2013-09-24 NZ NZ706147A patent/NZ706147A/en unknown
- 2013-09-24 PL PL13766523T patent/PL2900232T3/pl unknown
- 2013-09-24 RU RU2015110981A patent/RU2650618C2/ru active
- 2013-09-24 WO PCT/EP2013/069858 patent/WO2014048921A1/en not_active Ceased
- 2013-09-24 LT LTEP13766523.8T patent/LT2900232T/lt unknown
- 2013-09-24 DK DK13766523.8T patent/DK2900232T3/en active
- 2013-09-24 HU HUE13766523A patent/HUE036518T2/hu unknown
- 2013-09-24 CA CA2885792A patent/CA2885792C/en active Active
- 2013-09-24 MX MX2015003589A patent/MX368288B/es active IP Right Grant
- 2013-09-24 US US14/430,801 patent/US9579378B2/en active Active
- 2013-09-24 JP JP2015532454A patent/JP6426093B2/ja active Active
- 2013-09-24 BR BR112015006731A patent/BR112015006731A2/pt not_active Application Discontinuation
-
2015
- 2015-03-23 ZA ZA2015/01980A patent/ZA201501980B/en unknown
- 2015-03-24 IL IL237926A patent/IL237926B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20181090A1 (es) | Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38 | |
| RU2015110981A (ru) | Комбинации и их применение | |
| JP2017048208A5 (enExample) | ||
| PE20161571A1 (es) | Anticuerpos anti-ox40 y metodos de uso | |
| JP2016520514A5 (enExample) | ||
| JOP20210044A1 (ar) | الأجسام المضادة لـ cd38 | |
| AR081427A1 (es) | Metodo para preparar anticuerpos con propiedades mejoradas | |
| PE20150025A1 (es) | Anticuerpos e inmunoconjugados contra ly6e y metodos de uso | |
| HRP20171992T1 (hr) | Protutijela protiv cgrp | |
| NZ729158A (en) | Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use | |
| UA118332C2 (uk) | Білок, що зв'язує антиген cd27l | |
| MX348581B (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. | |
| HRP20191678T1 (hr) | Pd-1 protutijelo, njegov fragment koji se veže na antigen, i njegova medicinska primjena | |
| JP2013542194A5 (enExample) | ||
| UA118255C2 (uk) | Композиція, яка містить антитіло до cd38 і леналідомід | |
| HRP20160151T1 (hr) | PROTUTIJELA PROTIV N3pGlu-AMILOIDNOG BETA PEPTIDA I NJIHOVA UPOTREBA | |
| PE20141017A1 (es) | Anticuerpos del cea | |
| EA201401204A1 (ru) | Антитела к il-23p19 | |
| ES2685424T3 (es) | Anticuerpos anti-Jagged1 y procedimientos de uso | |
| RU2017137496A (ru) | Средство для лечения множественной миеломы (ММ) | |
| RU2015102069A (ru) | Антитела к биотину и способы их применения | |
| EA201301107A1 (ru) | Моноклональные антитела против ингибитора пути тканевого фактора (tfpi) | |
| JP2018515513A5 (enExample) | ||
| HRP20161587T1 (hr) | Protutijela protiv bmp-6 | |
| AR098663A1 (es) | Anticuerpos multifuncionales que se unen a egfr y met |